# Cordance Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cordance-medical

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.cordancemedical.com
- Total disclosed funding: $8M
- Latest round: Seed (Oct 21, 2025)
- Investors on record: 7

## About

Cordance Medical is a US-based company specializing in innovative medical devices aimed at enhancing treatment options for brain diseases by non-invasively accessing the brain's therapeutic environment.Cordance Medical was founded in 2018 in Mountain View, US, focusing on developing medical devices that can open the blood-brain barrier (BBB). The company has undergone strategic pivots to refine its technology and approach to market. The latest funding round was a Seed round in October 2025, raising USD 8.000 mn led by Sonder Capital, with multiple other investors participating. The total amount raised to date is USD 8.000 mn, with one recorded deal in its history.Cordance Medical's core product is the NeuroAccess™ medical device, which non-invasively and reversibly opens the blood-brain barrier at targeted brain sites. The device utilizes low-frequency focused ultrasound and microbubbles for precise delivery of therapeutic agents and biomarker measurement, targeting diseases such as brain cancer, Alzheimer's, Parkinson's, and epilepsy. The NeuroAccess™ device is designed for outpatient use across North America and Europe, aiming to improve diagnostic and therapeutic outcomes for patients.Cordance Medical generates revenue through partnerships with healthcare providers, pharmaceutical firms, and research institutions focused on marketing the NeuroAccess™ medical device. Revenue is anticipated from direct sales to healthcare facilities and potential subscription models for ongoing support and maintenance. The innovative nature of the device supports a pricing strategy reflecting its value to patient care.In October 2025, Cordance Medical raised USD 8.000 mn in Seed funding, with plans to utilize this capital to advance its first-in-human clinical trial. The company aims to expand into new markets in North America and Europe, enhancing its presence in the healthcare sector as it rolls out its NeuroAccess™ technology. Future initiatives will focus on product development and market penetration, aligning with the company's long-term growth strategy.

## Funding rounds

- Seed, Oct 21, 2025, $8M — Shanda Capital, SmartGateVC, Sonder Capital, Angel Physicians Fund, R42, Brain Tumor Investment Fund, Sontag Foundation

## Investors

- Shanda Capital — Seed
- SmartGateVC (https://capitalatlas.ai/funds/smartgatevc) — Seed
- Sonder Capital (https://capitalatlas.ai/funds/sonder-capital) — Seed
- Angel Physicians Fund (https://capitalatlas.ai/funds/angel-physicians-fund) — Seed
- R42 (https://capitalatlas.ai/funds/r42) — Seed
- Brain Tumor Investment Fund — Seed
- Sontag Foundation (https://capitalatlas.ai/funds/sontag-foundation) — Seed